Keith Julia L, Swinkin Emily, Gao Andrew, Alminawi Samira, Zhang Ming, McGoldrick Philip, McKeever Paul, Robertson Janice, Rogaeva Ekaterina, Zinman Lorne
Laboratory Medicine and Molecular Diagnostics (J.L.K., A.G., S.A.), Division of Anatomical Pathology, Sunnybrook Health Sciences Centre, University of Toronto; Department of Medicine (E.S., L.Z.), Division of Neurology, Sunnybrook Health Sciences Centre, University of Toronto, Ontario, Canada; School of Medicine and Institute for Advanced Study (M.Z.), Tongji University, Shanghai, China; and Tanz Centre for Research in Neurodegenerative Diseases (M.Z., P. McGoldrick, P. McKeever, J.R., E.R.), University of Toronto, Ontario, Canada.
Neurol Genet. 2020 Jan 13;6(1):e394. doi: 10.1212/NXG.0000000000000394. eCollection 2020 Feb.
To present the postmortem neuropathologic report of a patient with a mutation exhibiting an amyotrophic lateral sclerosis (ALS) clinical phenotype.
A 54-year-old man without significant medical history or family history presented with arm weakness, slowly progressed over 19 years to meet the El Escorial criteria for clinically probable ALS with bulbar and respiratory involvement, and was found to have a p.R15L mutation. Postmortem neuropathologic examination took place including immunohistochemical staining with CHCHD10, and double immunofluorescence combining CHCHD10 with TDP43 and neurofilament was performed and the results were compared with normal controls and sporadic ALS cases.
Postmortem examination of the mutation carrier showed severe loss of hypoglossal and anterior horn motor neurons, mild corticospinal tract degeneration, and a relative lack of TDP43 immunopathology. CHCHD10 immunohistochemistry for the 3 controls and the 5 sporadic ALS cases showed strong neuronal cytoplasmic and axonal labeling, with the mutation carrier also having numerous CHCHD10 aggregates within their anterior horns. These aggregates may be related to the CHCHD10 aggregates recently described to cause mitochondrial degeneration and disease in a tissue-selective toxic gain-of-function fashion in a CHCHD10 knock-in mouse model. The CHCHD10 aggregates did not colocalize with TDP43 and were predominantly extracellular on double immunofluorescence labeling with neurofilament.
The neuropathology of CHCHD10 mutated ALS includes predominantly lower motor neuron degeneration, absent TDP43 immunopathology, and aggregates of predominantly extracellular CHCHD10, which do not contain TDP43.
展示一名具有突变且表现为肌萎缩侧索硬化(ALS)临床表型患者的尸检神经病理学报告。
一名54岁男性,无重大病史或家族病史,出现手臂无力症状,在19年里缓慢进展,符合临床可能的ALS的埃尔埃斯科里亚尔标准,伴有延髓和呼吸受累,且发现有p.R15L突变。进行了尸检神经病理学检查,包括用CHCHD10进行免疫组织化学染色,并将CHCHD10与TDP43和神经丝进行双重免疫荧光检测,结果与正常对照和散发性ALS病例进行比较。
对该突变携带者的尸检显示舌下神经和前角运动神经元严重丧失,皮质脊髓束轻度变性,且TDP43免疫病理学表现相对缺乏。对3名对照和5例散发性ALS病例进行CHCHD10免疫组织化学检测显示,神经元胞质和轴突有强烈标记,该突变携带者的前角内也有大量CHCHD10聚集体。这些聚集体可能与最近在CHCHD10基因敲入小鼠模型中描述的以组织选择性毒性功能获得方式导致线粒体变性和疾病的CHCHD10聚集体有关。CHCHD10聚集体与TDP43不共定位,在与神经丝的双重免疫荧光标记中主要位于细胞外。
CHCHD10突变型ALS的神经病理学主要包括下运动神经元变性、缺乏TDP43免疫病理学以及主要为细胞外的不含TDP43的CHCHD10聚集体。